Related Experiment Video
Updated: Apr 9, 2026
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
18.2K
Dabigatran: Experience in standard clinical practice
J Álvarez-Otero1, J de la Fuente-Aguado1, J C Arias-Castaño2
1Servicio de Medicina Interna, Hospital Povisa, Vigo, España.
Revista Clinica Espanola
|June 23, 2015
Summary
Dabigatran effectively prevents stroke in patients with nonvalvular atrial fibrillation in clinical practice. This anticoagulant demonstrates a favorable safety profile, with low rates of ischemic events and manageable hemorrhagic complications.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Dabigatran, a direct thrombin inhibitor, is approved for preventing ischemic stroke in nonvalvular atrial fibrillation (NVAF).
- Real-world efficacy and safety data are crucial for understanding its clinical utility beyond trial settings.
Purpose of the Study:
- To evaluate the effectiveness of dabigatran in preventing cerebral ischemic events in NVAF patients.
- To assess the tolerance and safety profile of dabigatran in routine clinical practice.
Main Methods:
- A retrospective, descriptive study analyzed 316 patients treated with dabigatran from November 2011 to September 2012.
- Follow-up extended to June 2013, recording ischemic events (cerebral, cardiac, peripheral) and hemorrhagic complications.
Main Results:
- The study included 316 patients (mean age 76.46±8.37 years, 53.5% male).
- Low incidence of ischemic events: 0.55/100 patient-years for stroke and 2.18/100 patient-years for other ischemic events.
- Hemorrhagic complications occurred in 10.91/100 patient-years, with 2.18/100 patient-years being major hemorrhages.
Conclusions:
- Dabigatran is effective for stroke prevention in standard clinical practice for NVAF patients.
- The observed safety profile of dabigatran aligns with findings from pivotal clinical trials.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
01:29Venous Thrombosis III: Interprofessional Care
466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
676
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
676
01:11Clinical Trials: Overview
5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
441
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
441